471 results on '"Coffin, Robert"'
Search Results
2. Operation Dragoon: A forging of allies
3. Operation Torch: A perilous preview
4. Demonstration at Heidelberg--guts, good sense, great timing
5. Mission at Casablanca
6. 705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial
7. Supplementary Figures S1-S4 from Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
8. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
9. 575 Safety and feasibility of intratumoral injection of the RPx family of oncolytic immunotherapies in patients with liver metastasis
10. 611 Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial
11. 610 Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors
12. White paper on microbial anti-cancer therapy and prevention
13. Proteomics analysis suggests broad functional changes in potato leaves triggered by phosphites and a complex indirect mode of action against Phytophthora infestans
14. Abstract CT155: Clinical biomarker studies with an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors indicates potent immune activation
15. A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.
16. Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).
17. An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors.
18. 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors
19. 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors
20. 550 ARTACUS: An open-label, multicenter, phase 1b/2 study of RP1 in solid organ transplant recipients with advanced cutaneous malignancies
21. Appendix Y. The Integrated Communications Experiment (ICE) Summary.
22. Herpes Simplex Virus Infection of Dendritic Cells: Balance among Activation, Inhibition, and Immunity
23. Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation
24. Abstract 1917: Immunomodulatory effects of a novel, enhanced potency gibbon ape leukaemia virus (GALV) fusogenic membrane glycoprotein-expressing herpes simplex virus platform with increased efficacy combined with anti PD-1 therapy
25. Optimization of a Real-Time RT-PCR Assay and its Comparison with ELISA, Conventional RT-PCR and the Grow-out Test for Large Scale Diagnosis of Potato virus Y in Dormant Potato Tubers
26. Abstracts of papers presented at the 81st annual meeting of The Potato Association of America Charlottetown, P.E.I., Canada August 3 – 7, 1997
27. 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts
28. 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
29. In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors
30. Post-harvest Storage of Potatoes
31. Construction and Characterization of an Oncolytic HSV Vector Containing a Fusogenic Glycoprotein and Prodrug Activation for Enhanced Local Tumor Control
32. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
33. Assessing the suppressive effects of biopesticides and phosphite on common scab development in potatoes
34. An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.
35. Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma
36. Puppy in a Cyst: “Iʼm Trapped! Help Please!”
37. Gene delivery to rat enteric neurons using herpes simplex virus-based vectors
38. Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus
39. Additional file 1: of Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
40. Gene Therapy with Virus Vectors for specific Disease of the Nervous System
41. Novel Therapeutic Strategy for Stroke in Rats by Bone Marrow Stromal Cells and ex vivo HGF Gene Transfer with HSV-1 Vector
42. Examination of the potential interactions between herpes simplex virus vectors and replication-competent virus in vitro and in vivo
43. Abstract 1470: Development & characterization of a new oncolytic immunotherapy platform based on herpes simplex virus type 1
44. An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
45. Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo
46. Hydride complexes of ruthenium derived from the heterolytic activation of dihydrogen by amidophosphine complexes
47. ATF3 upregulation in glia during Wallerian degeneration: differential expression in peripheral nerves and CNS white matter
48. Appendix X. ComField Information Management System.
49. Letters to the Editor
50. Binuclear initiators for the telechelic synthesis of elastomeric polyolefins
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.